Activity of veltuzumab, a second-generation humanized anti-CD20 mAb, in laboratory and clinical studies

被引：0
|
作者：
Goldenberg, D. M. [2 ]
Chang, C. [6 ]
Rossi, E. A. [6 ]
Cardillo, T. M. [6 ]
Wegener, W. A. [6 ]
Teoh, N. [6 ]
Leonard, J. P. [5 ]
Fayad, L. [4 ]
Coiffier, B. [3 ]
Morschhauser, F. [1 ]
机构：
[1] Ctr Hosp Reg & Univ Lille, Serv Malad Sang, F-59037 Lille, France
[2] Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ USA
[3] Ctr Hosp Lyon Sud, Serv Hematol, Lyon, France
[4] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, New York, NY 10021 USA
[6] Res & Dev Immunomedics Inc, Morris Plains, NJ USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：130 / 130
页数：1
相关论文
共 50 条
  • [1] VELTUZUMAB Humanized Anti-CD20 Monoclonal Antibody Oncolytic
    Bhat, S. A.
    Czuczman, M. S.
    [J]. DRUGS OF THE FUTURE, 2011, 36 (07) : 519 - 526
  • [2] Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab
    Goldenberg, D. M.
    Chang, C.
    Rossi, E. A.
    Cardillo, T. M.
    Wegener, W. A.
    Teoh, N.
    Leonard, J. P.
    Fayad, L. E.
    Coiffier, B.
    Morschhauser, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects
    Goldenberg, David M.
    Morschhauser, Franck
    Wegener, William A.
    [J]. LEUKEMIA & LYMPHOMA, 2010, 51 (05) : 747 - 755
  • [4] Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris
    Ellebrecht, Christoph T.
    Choi, Eun J.
    Allman, David M.
    Tsai, Donald E.
    Wegener, William A.
    Goldenberg, David M.
    Payne, Aimee S.
    [J]. JAMA DERMATOLOGY, 2014, 150 (12) : 1331 - 1335
  • [5] Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb
    Goldenberg, David M.
    Govindan, Serengulam
    Cardillo, Tom M.
    Sharkey, Robert M.
    [J]. BLOOD, 2010, 116 (21) : 1607 - 1607
  • [6] Deleting Malignant B Cells With Second-Generation Anti-CD20 Antibodies
    Sopp, Josh
    Cragg, Mark S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2323 - +
  • [7] Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
    Goldenberg, David M.
    Rossi, Edmund A.
    Stein, Rhona
    Cardillo, Thomas M.
    Czuczman, Myron S.
    Hernandez-Ilizaliturri, Francisco J.
    Hansen, Hans J.
    Chang, Chien-Hsing
    [J]. BLOOD, 2009, 113 (05) : 1062 - 1070
  • [8] Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL.
    Morshhauser, F.
    Leonard, J. P.
    Coiffier, B.
    Petillon, M.
    Coleman, M.
    Bahkti, A.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 429S - 429S
  • [9] Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders
    Castillo, Jorge
    Milani, Cannon
    Mendez-Allwood, Daniel
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (04) : 491 - 500
  • [10] Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies
    Negrea, O. George
    Allen, Steven L.
    Rai, Kanti R.
    Elstrom, Rebecca
    Abassi, Rashid
    Farber, Charles M.
    Teoh, Nick
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    [J]. BLOOD, 2009, 114 (22) : 1446 - 1446
12345